Chronic Hepatitis Delta Virus (HDV)
MIRMMirum PharmaceuticalsCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Brelovitug (HBsAg Antibody) in Chronic Hepatitis Delta Virus (HDV). The expected timing is based on the latest available company guidance and may change.
AZURE-1 trial. 01/12/26:- Interim data in Q2 2026; topline data in H2 2026, subject to acquisition. 02/25/26:- AZURE-1 Phase 3 HDV trial interim data still expected Q2 2026 and topline data H2 2026. 03/05/26:- AZURE-1 enrollment complete; AZURE-4 screening complete. AZURE-1 interim data Q2 2026. 04/27/26:- AZURE-1 Ph2b met endpoint. Full results at EASL May 27-30, 2026. Ph3 topline H2 2026. BLA possible 2027. 05/06/26:- AZURE-1 Ph2b primary endpoint and EASL May 27 poster reiterated; AZURE-1 and AZURE-4 Ph3 enrollment now complete; topline H2 2026. 05/30/26:- AZURE-1 Ph2b Week 24 efficacy/safety presented. Ph3 AZURE-1/4 topline expected H2 2026. 08/05/26:- AZURE-1 Ph3 topline results expected Q3 2026; AZURE-4 expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.